Ruxolitinib
Cross-source consensus on Ruxolitinib from 1 sources and 7 claims.
1 sources · 7 claims
How it works
Benefits
Dosage & preparation
Comparisons
Highlighted claims
- Ruxolitinib inhibits JAK1 and JAK2, thereby suppressing the JAK/STAT signalling pathway. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Cytokine-induced STAT3 phosphorylation is inhibited within 2 hours of ruxolitinib administration, producing downstream reductions in TNF-alpha, IL-6, and CRP. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- A low-to-intermediate ruxolitinib dose was chosen for MATIS out of concern for immunosuppression during the active phase of viral infection. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- No deaths occurred in the ruxolitinib arm within the first 14 days of the trial. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- The RuxCoFlam trial demonstrated a significant benefit of ruxolitinib and used a composite inflammation score requiring far more extreme CRP elevations than MATIS. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Ruxolitinib showed a numerically lower rate of severe pneumonia than standard of care (16.1% vs 24.6%), but this did not reach statistical significance. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Higher ruxolitinib doses or longer treatment durations may be more appropriate for more severe COVID-19. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic